^
Association details:
Biomarker:BBOX1 underexpression
Cancer:Renal Cell Carcinoma
Drug:GSK690693 (AKT inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Low gamma-butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach

Published date:
03/02/2023
Excerpt:
In vitro drug screening showed that midostaurin, BAY-61-3606, GSK690693, and linifanib inhibited the growth of RCC cells with low BBOX1 expression.
DOI:
10.1002/cjp2.315